Axsome Therapeutics
Seite 3 von 6 Neuester Beitrag: 13.02.23 16:27 | ||||
Eröffnet am: | 31.05.17 18:55 | von: Mr. Gantzer | Anzahl Beiträge: | 146 |
Neuester Beitrag: | 13.02.23 16:27 | von: Vassago | Leser gesamt: | 53.431 |
Forum: | Hot-Stocks | Leser heute: | 31 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | | 4 | 5 | 6 > |
war bagholder und bin froh draussen zu sein mit Gewinn ...
Wir werden meines Erachtens schon bald zweistellige Kurse sehen, zumal das Unternehmen sich gestern sehr professionell zu Kursen um 8 USD
frisches Geld besorgt hat und damit den Short-Sellern jeden Wind aus den Segeln genommen hat.
23,3 Mio. $ ATM Finanzierung
"Axsome Therapeutics, Inc. a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that today it raised approximately $23.3 million through the sale of 2,881,066 shares under its existing at-the-market (ATM) facility with Leerink Partners LLC."
https://axsometherapeuticsinc.gcs-web.com/...ews_date_value[min]=2019
AXS-12 Phase II Studie beginnt
https://seekingalpha.com/news/...d-stage-study-axsminus-12-narcolepsy
Axsome meldet Zahlen für 2018
- keine Umsätze
- Verlust 31 Mio. $
- Verlust in Q4 ~10 Mio. $
- Verlust in Q4 ~10 Mio. $
- Cash 14 Mio. $
- MK 311 Mio. $
"At December 31, 2018, Axsome had $14.0 million of cash. Including proceeds from the recently completed at-the-market equity financings and new growth capital term loan, Axsome’s pro forma cash balance was $52.6 million [...]
Axsome anticipates that its current cash, including proceeds from the January 2019 equity financings and March 2019 term loan, will be sufficient to fund its anticipated operations, based on its current operating plans, into at least the fourth quarter of 2021."
https://axsometherapeuticsinc.gcs-web.com/...ews_date_value[min]=2019